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ABSTRACT
Introduction. In this edition, Szymuś et al. conducted a systematic review revealing sexual dysfunction to be more prevalent 
in patients with Huntington’s Disease compared to controls. 
Clinical reflections. Sexual dysfunction in HD (SDHD) is common and significantly affects patient quality of life. Commonly used HD 
rating scales and treatment guidelines do not explicitly address SDHD, and research studies are limited by size and methodology.
Clinical implications. It is important that validated sexual dysfunction screening tools be utilised in clinical and research 
settings.
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Huntington’s Disease (HD) is a dominantly inherited neuro-
degenerative disease caused by an expanded CAG trinucleo-
tide repeat in the HTT gene, which encodes the huntingtin 
protein [1]. Symptoms of HD include a classic triad of move-
ment abnormalities, cognitive impairment, and behavioural 
disturbances. Due to genetic anticipation, these symptoms 
occur earlier, and more severely, with successive generations 
[2]. HD affects people during the prime years of life with an 
average age at onset of between 30 and 50 [3]. While HD is 
rare, affecting only 2.71 per 100,000 people worldwide [4], 
associated symptoms cause significant functional impairment 
[5]. HD is the most common cause of inherited chorea, and 
clinicians may focus on the movement disorder at the expense 
of other symptoms that cause as much, if not more, detriment 
to quality of life (QoL).
Szymuś et al. conducted a systematic review of HD-asso-
ciated sexual dysfunction [6]. They found that the majority 
of patients with HD had sexual disorders, particularly hypo/
hyperactive sexual disorder, erectile and ejaculatory dysfun-
ction, lubrication problems, and orgasmic dysfunction. Their 
findings suggest that SD is more common in HD and correlates 
with QoL measures [6]. However, their review also illuminates 
several limitations of the current literature regarding SDHD.
Firstly, the HD literature has consistently underinvestiga-
ted sexual function. The DSM-5 has an entire chapter on SD, 
which includes delayed ejaculation, erectile disorder, female 
orgasmic disorder, female sexual interest/arousal disorder, 
genito-pelvic pain/penetration disorder, male hypoactive 
sexual desire disorder, premature ejaculation, substance/
medication-induced SD, and others [7]. This categorisation 
alone illustrates the variety of elements to consider when 
evaluating patients for SD. However, widely used HD rating 
scales e.g. UHDRS and UHDRS-FAP, and current treatment 
guidelines, do not address SD at all [8–11]. 
Therefore, it is not surprising that SDHD has been oversha-
dowed by other disease symptoms such as chorea. Moreover, 
conducting a thorough assessment of sexual function can be 
time-consuming for clinicians and awkward or uncomfor-
table for patients and their partners. This method of verbal 
assessment can lead to underreporting of sexual dysfunction 
for a variety of reasons relating to one’s culture, belief set, or 
social factors. Validated sexual function scales can help with 
this problem. The international index of erectile function 
(IIEF) assesses erectile function, orgasmic function, sexual de-
sire and intercourse satisfaction in males [12]. For females, the 
female sexual function index (FSFI) yields a valid assessment of 
sexual domains including desire, arousal, lubrication, orgasm, 
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satisfaction and pain [13]. Validated scales such as the IIEF 
and FSFI should be the standard for future studies.
Another limitation of the literature is a simple lack of 
well-designed, fully-powered studies focusing on SDHD as 
a primary endpoint. Szymuś et al. found only nine studies 
conducted over a 25-year timespan. These included informa-
tion on sexual function of at least 20 genetically confirmed 
HD patients [6]. These studies were conducted an average of 
11 years ago, and one third were conducted more than 18 years 
ago. There also seems to be an inverse relationship between 
study size and data quality. The largest study, of more than 
2,500 patients, used unvalidated online survey questions with 
no control group [14]. Only two small trials used validated 
sexual function scales i.e. the IIEF [15] and the FSFI [16]. Non-
-standardised study methodology, and an apparent trade-off 
between study size and quality, inhibit us from developing 
reliable conclusions.
A recent study found that SDHD resulted in the highest 
life impact among 216 HD-related symptoms [5]. Despite 
this substantial effect on QoL, we know little about the me-
chanisms underlying SDHD. It is unclear whether the SD is 
directly caused by the HD pathomechanism, or whether it is 
merely a byproduct of other symptoms and/or their treatments. 
Depression is prevalent in HD [17] and is directly related to 
erectile/ejaculatory problems [18]. Dopamine depleting agents 
such as tetrabenazine are effective and widely used to treat 
HD-related chorea [19]; however, this mechanism can also 
cause depressive symptoms or exacerbate preexisting depres-
sion [20]. There is also a well-established association between 
antidepressants and SD [21]. These are just some of the factors 
that are likely to be contributory to SDHD.
This is an exciting time for HD research, with the deve-
lopment of enhanced rehabilitative strategies and promising 
disease-modifying treatments such as antisense oligonuc-
leotides (ASO) [22–24]. It remains to be seen how these 
interventions will affect patients at different disease stages. 
Further research is required to study large patient groups using 
validated assessment tools. Lastly, clinicians should remember 
that SDHD substantially affects QoL, and that patients frequ-
ently withhold such information due to a variety of cultural 
and societal factors.
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